Richard K. Sterling

Dr. Richard K. Sterling

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
ADAndres Duarte-Rojo
Andres Duarte-Rojo
KPKeyur Patel
Keyur Patel
SASumeet K. Asrani
Sumeet K. Asrani
MAMouaz Alsawas
Mouaz Alsawas
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
KPKeyur Patel
Keyur Patel
ADAndres Duarte-Rojo
Andres Duarte-Rojo
SASumeet K. Asrani
Sumeet K. Asrani
MAMouaz Alsawas
Mouaz Alsawas
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.

25 June 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
BBBubu A Banini
Bubu A Banini
YAYahya Alwatari
Yahya Alwatari
MSMadeline Stovall
Madeline Stovall
NONathan Ogden
Nathan Ogden
EGEvgeni Gershman
Evgeni Gershman
RSRichard K. Sterling
Richard K. Sterling

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
ADAndres Duarte-Rojo
Andres Duarte-Rojo
BTBachir Taouli
Bachir Taouli
DLDaniel H. Leung
Daniel H. Leung
DLDeborah Levine
Deborah Levine
TNTarek Nayfeh
Tarek Nayfeh
RSRichard K. Sterling
Richard K. Sterling
Background and Aims: Transient elastography (TE), shear wave elastography, and/or magnetic resonance elastography (MRE), each providing liver stiffness measurement (LSM), are the most studied imaging-based noninvasive liver disease assessment (NILDA) techniques. To support the American Association for the Study of Liver Diseases guidelines on NILDA, we summarized the evidence on the accuracy of these LSM methods to stage liver fibrosis (F). Approach and Results: A comprehensive search for studies assessing LSM by TE, shear wave elastography, or MRE for the identification of significant fibrosis (F2-4), advanced fibrosis (F3-4), or cirrhosis (F4), using histopathology as the standard of reference by liver disease etiology in adults or children from inception to April 2022 was performed. We excluded studies with <50 patients with a single disease entity and mixed liver disease etiologies (with the exception of HCV/HIV coinfection). Out of 9447 studies, 240 with 61,193 patients were included in this systematic review. In adults, sensitivities for the identification of F2-4 ranged from 51% to 95%, for F3-4 from 70% to 100%, and for F4 from 60% to 100% across all techniques/diseases, whereas specificities ranged from 36% to 100%, 74% to 100%, and 67% to 99%, respectively. The largest body of evidence available was for TE; MRE appeared to be the most accurate method. Imaging-based NILDA outperformed blood-based NILDA in most comparisons, particularly for the identification of F3-4/F4. In the pediatric population, imaging-based NILDA is likely as accurate as in adults. Conclusions: LSM from TE, shear wave elastography, and MRE shows acceptable to outstanding accuracy for the detection of liver fibrosis across various liver disease etiologies. Accuracy increased from F2-4 to F3-4 and was the highest for F4. Further research is needed to better standardize the use of imaging-based NILDA, particularly in pediatric liver diseases.

16 June 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
MGMarc G. Ghany
Marc G. Ghany
WKWendy C. King
Wendy C. King
MLMauricio Lisker‐Melman
Mauricio Lisker‐Melman
ALAnna S.F. Lok
Anna S.F. Lok
NTNorah Terrault
Norah Terrault
RSRichard K. Sterling
Richard K. Sterling
Background and Aims: The clinical utility of two biomarkers, hepatitis B virus (HBV) RNA and hepatitis B core‐related antigen (HBcrAg), as compared to conventional markers of HBV replication and disease activity, is unclear. Approach and Results: Untreated participants in the North American Hepatitis B Research Network Adult Cohort Study were categorized by chronic hepatitis B (CHB) phases based on HBsAg and HBeAg status and HBV DNA and alanine aminotransferase (ALT) levels. HBV RNA and HBcrAg were measured (Abbott HBV pgRNA Research Assay and Fujirebio Lumipulse Immunoassay, respectively), and cross‐sectional associations with conventional CHB markers were tested. Among 1,409 participants across all CHB phases, median HBV DNA was 3.8 log10 IU/mL and ALT was 34 U/L. HBV RNA was quantifiable in 99% of HBeAg+ and 58% of HBeAg− participants; HBcrAg was quantifiable in 20% of HBeAg+ (above linear range in the other 80%) and 51% of HBeAg− participants. Both markers differed across CHB phases (P < 0.001), with higher levels in the HBeAg+ and HBeAg− immune active phases. HBV RNA and HBcrAg correlated moderately strongly with HBV DNA in both HBeAg+ and HBeAg− phases (HBV RNA: e+ ρ = 0.84; e− ρ = 0.78; HBcrAg: e+ ρ = 0.66; e− ρ = 0.56; P for all, <0.001), but with HBsAg levels among HBeAg+ phases only (HBV RNA: e+ ρ = 0.71; P < 0.001; e− ρ = 0.18; P = 0.56; HBcrAg: e+ ρ = 0.51; P < 0.001; e− ρ = 0.27; P < 0.001). Associations of higher HBV RNA and HBcrAg levels with higher ALT, APRI, and Fibrosis‐4 levels were consistent in HBeAg−, but not HBeAg+, phases. Conclusions: Despite clear relationships between HBV RNA and HBcrAg levels and CHB phases, these markers have limited additional value in differentiating CHB phases because of their strong association with HBV DNA and, to a lesser extent, with clinical disease indicators.

22 September 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
AFAndrew Fagan
Andrew Fagan
EGEdith A. Gavis
Edith A. Gavis
MGMary Leslie Gallagher
Mary Leslie Gallagher
TMTravis Mousel
Travis Mousel
BDBrian Davis
Brian Davis
JBJasmohan Bajaj
Jasmohan Bajaj